In addition to describing current and projected

prevalence estimates of substance abuse among older adults, the present review discusses how aging affects brain systems involved in drug abuse, and explores the potential impact of drug abuse on the aging brain. Future directions for substance abuse research among older adults will also be considered.”
“Aim. The onset of posttransplant diabetes mellitus (PTDM) among kidney recipients is associated with an increased risk of graft failure and death. Minimizing the risk of PTDM is a priority for long-term improvement in survival rates. We sought to evaluate the prevalence of PTDM and impaired fasting glucose (IFG) among a population of kidney transplant recipients to identify the risk factors selleck chemical and to evaluate graft and patient survivals.\n\nMethods. We analyzed 250 consecutive Caucasian patients who received kidney allografts in our center between May 2000 and December 2005, with a median follow-up of 32 months (range, 1.-78 months).\n\nResults. We observed altered glucose metabolism in 17% of patients; specifically, the prevalences of PTDM and IFG were 12.2% and 4.8%, respectively. Patients who 2 developed PTDM or IFG were overweight (BMI, 26.4 +/- 3.4

and 28.1. +/- 3.4 kg/m(2) respectively), whereas the normal glucose HDAC inhibitor review (NG) group’s BMI was 23.8 +/- 3.5 kg/m(2) (P = .002 and P = .004, respectively). Prevalence of acute rejection was higher in the PTDM and IFG patients compared with the NG patients (60.7%, 63.6%, and 32.1%, respectively; Nepicastat manufacturer P = .006; P < .04), while no difference was observed in terms of graft and patient overall survival.\n\nConclusion. In our series of patients, we showed that being overweight represents a major risk factor for the development of PTDM, which results in an increased acute rejection

rate. These results confirmed the importance of appropriate weight control among patients undergoing kidney transplantation, which should also be strictly monitored for all risk factors associated with the development of impaired glucose metabolism.”
“Standard first-line therapy for older patients with high-risk myelodysplastic syndrome (MDS) includes hypomethylating agents, such as azacitidine (AZA). However, the only approach with curative potential remains allogeneic hematopoietic cell transplantation (HCT). To date, no direct comparison of both strategies has been reported. The outcomes of 2 well-balanced cohorts of patients with high-risk MDS defined by age (60-70 years), performance status (Eastern Cooperative Oncology Group score <= 2), and donor availability (yes/no) were compared, including 103 patients undergoing HCT and 75 patients without this option who received AZA.